AUTHOR=Nowrouzi-Sohrabi Peyman , Soroush Negin , Tabrizi Reza , Shabani-Borujeni Mojtaba , Rezaei Shahla , Jafari Fatemeh , Hosseini-Bensenjan Mahnaz , Stricker Bruno H. , van Hoek Mandy , Ahmadizar Fariba 

TITLE=Effect of Liraglutide on Cardiometabolic Risk Profile in People with Coronary Artery Disease with or without Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

JOURNAL=Frontiers in Pharmacology

VOLUME=12

YEAR=2021

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.618208

DOI=10.3389/fphar.2021.618208

ISSN=1663-9812

ABSTRACT=<p><bold>Background</bold>: Whether liraglutide use improves cardiometabolic risk factors in different subsets of subjects with coronary artery disease (CAD) remains unclear. In a systematic review and meta-analysis, we quantified the effects of liraglutide on cardiometabolic risk profile in subjects with CAD with or without type 2 diabetes mellitus (T2D).</p><p><bold>Methods</bold>: Online database searches were conducted in PubMed, Scopus, EMBASE, Web of Science, Cochrane library, and Google Scholar from incept up to 15th January 2021. We identified randomized controlled trials (RCTs) assessing the effects of liraglutide compared to placebo on cardiometabolic risk profile. We used the random- or fixed-effect models to pool the weighted mean differences (WMDs) and 95% confidence intervals (CIs).</p><p><bold>Results</bold>: Out of a total of 7,320 citations, six articles (seven RCTs) with 294 subjects with CAD (mean age, 61.21 years; 19% women) were included. Our findings presented as WMD and 95% CI showed a statistical significant decrease in hemoglobin A1c (HbA1c) [−0.36%; −0.47; −0.26, <italic>p</italic> &lt; 0.001; <italic>I</italic><sup>2</sup> = 0.0% (with 6 RCTs)], body mass index (BMI) [−0.61 kg/m<sup>2</sup>; −1.21; −0.01, <italic>p</italic> = 0.047; <italic>I</italic><sup>2</sup> = 72.2% (with five RCTs)], and waist circumference [−2.41 cm; −3.47; −1.36, <italic>p</italic> &lt; 0.001; <italic>I</italic><sup>2</sup> = 0.0% (with three RCTs)]. Through a set of subgroup analyses, we found a significant reduction in BMI in CAD patients with T2D [WMD = −1.06; 95% CI, −1.42, −0.70, <italic>p</italic> &lt; 0.001; <italic>I</italic><sup>2</sup> = 0.0% (with three RCTs)] compared to CAD only patients [WMD = −0.08; 95% CI, −0.45, 0.29, <italic>p</italic> = 0.66; <italic>I</italic><sup>2</sup> = 0.0% (with two RCTs)] in the liraglutide group compared with the placebo group. No significant changes in heart rate, blood pressure, and lipid profiles were observed.</p><p><bold>Conclusions</bold>: Among people with established CAD, liraglutide significantly improved HbA1c, BMI, and waist circumference values. The effect of liraglutide on BMI was more robust in individuals with T2D compared to those without.</p>